NGR-hTNF: Additional Phase II data

Additional data from the open-label, Italian Phase II NGR007 trial in 28 patients showed that 0.8 µg/m 2 IV NGR-hTNF plus doxorubicin led to 6 partial responses, plus 9 cases of stable disease. Additi...